In terms of potential intervention due to altered levels of adiponectin and resistin in T2DM concerning metabolic factors, atorvastatin, as the example of statin therapeutic intervention with antioxidant potential, did not influence the status of adiponectin and resistin, as suggested in research by Shetty et al. Additionally, in the aforementioned cross-sectional study, they noticed that despite decreased CRP levels with atorvastatin intervention, which might implicate that inflammation is not a mechanism by which adipokines interact in human pathophysiology [32]. This evidence concerns the gene CRP and type 2 diabetes mellitus.